Skip to main content
. 2021 Jul 7;297(2):100941. doi: 10.1016/j.jbc.2021.100941

Figure 2.

Figure 2

Modulation of Nprc expression by rosiglitazone and PPARγ.A, mRNA levels of Nprc and Fabp4 in 3T3-L1 adipocytes after treatment with 1 μM rosiglitazone (Rosi) or vehicle (Veh) for 6 h. B, mRNA levels of Nprc, Fabp4, and Pparγ1/2 mRNA in 3T3-L1 adipocytes after siRNA knockdown of Pparγ (siPparγ). C, protein levels of PPARγ1/2, NPRC, FABP4, and ADIPOQ in 3T3-L1 adipocytes after siPparγ. D, mRNA levels of Nprc and Fabp4 in NIH-3T3 cells (NIH) and NIH-3T3 cells stably expressing PPARγ (NIH-PPARγ) after treatment with 1 μM rosiglitazone (Rosi) or vehicle (Veh) for 6 h. Quantitative PCR data were normalized with 36B4. Student's t test, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001. Fabp4, fatty acid–binding protein 4; NIH, National Institutes of Health; Nprc, NP receptor C; ns, not significant; PPARγ, peroxisome proliferator–activated receptor gamma.